Developer docs
API playgroundTry for free, no card

Search company profiles

Rznomics

Full company profile

uuid0000rou

Namestring
Rznomics
Legal namestring
Rznomics Inc.
Websiteurl
rznomics.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Rznomics Inc. is a South Korean clinical-stage biopharmaceutical company founded in 2017 and headquartered in Seongnam, South Korea, that develops RNA editing-based gene therapies built on its proprietary RNA trans-splicing ribozyme platform. Unlike DNA-level editing approaches, the platform performs precise genetic corrections at the RNA level via trans-splicing, theoretically offering improved safety by avoiding permanent genomic alteration. Its lead investigational candidate, RZ-001, is in Phase 1/2a development for hepatocellular carcinoma (HCC) and recurrent glioblastoma; interim HCC data presented at AACR 2026 showed a 61.5% objective response rate and 23% complete response rate (mRECIST) when RZ-001 was combined with atezolizumab and bevacizumab, with no Grade 3+ adverse events attributed to RZ-001, while the Phase 1/2a glioblastoma trial enrolled 10 patients with no dose-limiting toxicity and disease control exceeding six months in several patients. RZ-001 has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in HCC, providing accelerated regulatory pathways including priority and rolling review and accelerated approval eligibility.

The company monetizes primarily through licensing and milestone-based partnerships with major pharmaceutical companies rather than direct product sales. In May 2026 Rznomics signed a global licensing agreement with Eli Lilly valued at up to $1.3 billion (upfront, research funding, and milestones) for hereditary hearing loss treatment development, marking entry into full implementation of joint R&D. It has also signed a strategic MOU with GluGene Therapeutics to combine its RNA editing platform with GluGene's AI-based AAV vector discovery technology for next-generation gene therapy delivery. Rznomics became a publicly listed company on KOSDAQ (ticker 476830) in December 2025, raising approximately $31 million, having previously raised approximately $64 million across Series A, B, and C rounds (2019–2024). Customer segments are organized vertically by indication: HCC patients, recurrent glioblastoma patients, and hereditary hearing loss patients, with the company operating in South Korea, the United States, and Japan.

Short descriptiontext

Rznomics Inc. is a South Korean clinical-stage biopharmaceutical company developing RNA editing-based gene therapies built on its proprietary trans-splicing ribozyme platform, with lead candidate RZ-001 in trials for hepatocellular carcinoma and glioblastoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA editing therapeutics, gene therapy drugs, biopharmaceutical development, cancer gene therapy, precision medicine
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
RNA Editing Gene Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Rznomics generates revenue through licensing agreements with pharmaceutical companies, including upfront payments, research funding, and milestone-based payments tied to development, regulatory, and commercial achievements. The company received research funding from Eli Lilly and entered full implementation phase of joint R&D.

healthcareasiamagazine.com
2Therapeutic Product Revenue
TypeOne Time License
Description

Future revenue expected from commercialization of RNA editing-based therapeutics following regulatory approval. The company is advancing RZ-001 through clinical development for hepatocellular carcinoma and glioblastoma, with plans to leverage FDA RMAT designation for accelerated approval pathways.

prnewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Rznomics is a South Korean clinical-stage biopharmaceutical company developing RNA editing-based gene therapies, with lead candidate RZ-001 in Phase 1/2a trials for hepatocellular carcinoma and recurrent glioblastoma. The company operates a proprietary RNA trans-splicing ribozyme platform that enables precision RNA editing without permanent DNA alterations, and monetizes its pipeline primarily through licensing deals and co-development partnerships with major pharmaceutical companies such as Eli Lilly.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 61.5% objective response rate with 23% complete response rate (mRECIST criteria) in hepatocellular carcinoma patients
+2 more records
Product overview1 text field

Rznomics is a South Korean biopharmaceutical company developing RNA-based gene therapies. The company's lead product is RZ-001, an RNA editing-based anticancer gene therapy currently in Phase 1/2a clinical trials for recurrent glioblastoma and hepatocellular carcinoma. The therapy is built on Rznomics' proprietary RNA trans-splicing ribozyme platform technology, which enables precision editing of RNA molecules for therapeutic purposes. The company has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RZ-001 in hepatocellular carcinoma.

Product and service2 records
1RZ-001
CategoryRNA editing gene therapy
Description

Investigational RNA editing-based anticancer gene therapy utilizing the proprietary RNA trans-splicing ribozyme platform for precision RNA editing in patients with hepatocellular carcinoma and recurrent glioblastoma.

2RNA Trans-Splicing Ribozyme Platform
CategoryRNA editing platform technology
Description

Proprietary RNA editing technology platform enabling precise genetic corrections via trans-splicing mechanisms, licensed to pharmaceutical partners for therapeutic applications across cancer and genetic diseases.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1GluGene Therapeutics
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-01
Description

Strategic MOU signed to jointly develop next-generation RNA gene therapies using adeno-associated virus (AAV) delivery platforms. The collaboration combines Rznomics' RNA trans-splicing enzyme-based precision editing platform with GluGene's AI-based AAV vector discovery technology, aiming to overcome technical challenges including transgene size capacity, tissue specificity, immune responses, and low-dose delivery efficiency.

koreabiomed.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

Global license agreement with Eli Lilly for hereditary hearing loss treatment development, valued at over $1.3 billion. The partnership includes research funding separate from upfront payments and marks entry into full implementation phase of joint R&D. Rznomics plans to use funds to advance its RNA correction platform and hearing loss program, with potential expansion into central nervous system diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing base editing therapies that chemically convert one DNA letter to another without double-stranded breaks. Like Rznomics, Beam operates in the precision genetic medicine space, pursuing targeted editing approaches for serious diseases with platform-based pipeline expansion.

TypeDirect peer
Description

Biotechnology company developing RNA editing therapeutics using ADAR-mediated single-base editing. Directly comparable to Rznomics' RNA editing approach via a different enzymatic mechanism; both pursue indication-agnostic platform strategies for genetic diseases.

TypeDirect peer
Description

Clinical-stage company using RNA editing to treat genetic diseases by reprogramming RNA. Ascidian shares Rznomics' focus on RNA-level rather than DNA-level editing, making it a direct technology comparable in modality and therapeutic ambition.

TypeDirect peer
Description

RNA therapeutics company developing Axiomer RNA editing technology and other RNA-targeting platforms. ProQR shares Rznomics' strategic positioning around RNA-based precision medicines and pursues similar rare disease and genetic disorder indications.

TypeDirect peer
Description

Clinical-stage company leveraging proprietary PRISM platform for RNA-targeted therapeutics including RNA editing. Wave's siRNA and RNA editing programs overlap with Rznomics' trans-splicing approach in modality and target disease areas.

TypeDirect peer
Description

Clinical-stage gene editing company developing in vivo CRISPR/Cas9-based therapies. Comparable to Rznomics as a peer in the precision genomic medicine space, though Intellia uses DNA-level editing while Rznomics edits RNA.

TypeDirect peer
Description

Clinical-stage company developing CRISPR-based genome editing therapies for serious diseases. Comparable in business model (clinical-stage gene medicine developer) and therapeutic ambition, though Rznomics differentiates via RNA editing.

TypeDirect peer
Description

Leading clinical-stage gene editing company with approved therapy (Casgevy) and broad pipeline across hemoglobinopathies, oncology, and regenerative medicine. Comparable as a clinical-stage gene medicine company with platform technology approach.

TypeDirect peer
Description

Clinical-stage company developing in vivo base editing therapies for cardiovascular disease. Comparable as a clinical-stage precision gene medicine developer pursuing platform-based indication expansion, with similar partnership-driven commercialization model.

TypeDirect peer
Description

Clinical-stage genomic medicine company developing zinc finger nuclease-based gene editing and gene therapy. Comparable as a clinical-stage platform company in genomic medicine with multiple pipeline programs and partnership-based commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rznomics

RNA Editing Gene Therapeuticsrznomics.com

Rznomics Inc. is a South Korean clinical-stage biopharmaceutical company developing RNA editing-based gene therapies built on its proprietary trans-splicing ribozyme platform, with lead candidate RZ-001 in trials for hepatocellular carcinoma and glioblastoma.

What Rznomics does

Rznomics Inc. is a South Korean clinical-stage biopharmaceutical company founded in 2017 and headquartered in Seongnam, South Korea, that develops RNA editing-based gene therapies built on its proprietary RNA trans-splicing ribozyme platform. Unlike DNA-level editing approaches, the platform performs precise genetic corrections at the RNA level via trans-splicing, theoretically offering improved safety by avoiding permanent genomic alteration. Its lead investigational candidate, RZ-001, is in Phase 1/2a development for hepatocellular carcinoma (HCC) and recurrent glioblastoma; interim HCC data presented at AACR 2026 showed a 61.5% objective response rate and 23% complete response rate (mRECIST) when RZ-001 was combined with atezolizumab and bevacizumab, with no Grade 3+ adverse events attributed to RZ-001, while the Phase 1/2a glioblastoma trial enrolled 10 patients with no dose-limiting toxicity and disease control exceeding six months in several patients. RZ-001 has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in HCC, providing accelerated regulatory pathways including priority and rolling review and accelerated approval eligibility.

The company monetizes primarily through licensing and milestone-based partnerships with major pharmaceutical companies rather than direct product sales. In May 2026 Rznomics signed a global licensing agreement with Eli Lilly valued at up to $1.3 billion (upfront, research funding, and milestones) for hereditary hearing loss treatment development, marking entry into full implementation of joint R&D. It has also signed a strategic MOU with GluGene Therapeutics to combine its RNA editing platform with GluGene's AI-based AAV vector discovery technology for next-generation gene therapy delivery. Rznomics became a publicly listed company on KOSDAQ (ticker 476830) in December 2025, raising approximately $31 million, having previously raised approximately $64 million across Series A, B, and C rounds (2019–2024). Customer segments are organized vertically by indication: HCC patients, recurrent glioblastoma patients, and hereditary hearing loss patients, with the company operating in South Korea, the United States, and Japan.

Rznomics firmographics

Firmographics
Name
Rznomics
Legal name
Rznomics Inc.
Website
https://rznomics.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Rznomics Inc. is a South Korean clinical-stage biopharmaceutical company developing RNA editing-based gene therapies built on its proprietary trans-splicing ribozyme platform, with lead candidate RZ-001 in trials for hepatocellular carcinoma and glioblastoma.
Ownership category
akta.pro rank

Where Rznomics is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Rznomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: Rznomics generates revenue through licensing agreements with pharmaceutical companies, including upfront payments, research funding, and milestone-based payments tied to development, regulatory, and commercial achievements. The company received research funding from Eli Lilly and entered full implementation phase of joint R&D.
  2. Therapeutic Product Revenue: Future revenue expected from commercialization of RNA editing-based therapeutics following regulatory approval. The company is advancing RZ-001 through clinical development for hepatocellular carcinoma and glioblastoma, with plans to leverage FDA RMAT designation for accelerated approval pathways.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Rznomics product offering

Product offering

Core offering

Rznomics is a South Korean clinical-stage biopharmaceutical company developing RNA editing-based gene therapies, with lead candidate RZ-001 in Phase 1/2a trials for hepatocellular carcinoma and recurrent glioblastoma. The company operates a proprietary RNA trans-splicing ribozyme platform that enables precision RNA editing without permanent DNA alterations, and monetizes its pipeline primarily through licensing deals and co-development partnerships with major pharmaceutical companies such as Eli Lilly.

Product overview

Rznomics is a South Korean biopharmaceutical company developing RNA-based gene therapies. The company's lead product is RZ-001, an RNA editing-based anticancer gene therapy currently in Phase 1/2a clinical trials for recurrent glioblastoma and hepatocellular carcinoma. The therapy is built on Rznomics' proprietary RNA trans-splicing ribozyme platform technology, which enables precision editing of RNA molecules for therapeutic purposes. The company has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for RZ-001 in hepatocellular carcinoma.

Differentiator

Problem solved

Functional benefit

Products and services

  • RZ-001 Investigational RNA editing-based anticancer gene therapy utilizing the proprietary RNA trans-splicing ribozyme platform for precision RNA editing in patients with hepatocellular carcinoma and recurrent glioblastoma.
  • RNA Trans-Splicing Ribozyme Platform Proprietary RNA editing technology platform enabling precise genetic corrections via trans-splicing mechanisms, licensed to pharmaceutical partners for therapeutic applications across cancer and genetic diseases.

Quantifiable outcome

  • 61.5% objective response rate with 23% complete response rate (mRECIST criteria) in hepatocellular carcinoma patients
  • +2 more outcomes

Companies that use Rznomics

Customer profile

Segments3 records

Ideal customer profiles1 record

Rznomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Rznomics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • GluGene TherapeuticscoreTechnology or Integration · 1 February 2026Strategic MOU signed to jointly develop next-generation RNA gene therapies using adeno-associated virus (AAV) delivery platforms. The collaboration combines Rznomics' RNA trans-splicing enzyme-based precision editing platform with GluGene's AI-based AAV vector discovery technology, aiming to overcome technical challenges including transgene size capacity, tissue specificity, immune responses, and low-dose delivery efficiency.
  • Eli LillyflagshipStrategic or Co-development Partner · 1 May 2025Global license agreement with Eli Lilly for hereditary hearing loss treatment development, valued at over $1.3 billion. The partnership includes research funding separate from upfront payments and marks entry into full implementation phase of joint R&D. Rznomics plans to use funds to advance its RNA correction platform and hearing loss program, with potential expansion into central nervous system diseases.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Rznomics competitors and assessment

Company assessment

Direct peers

  • Beam Therapeutics: Clinical-stage biotechnology company developing base editing therapies that chemically convert one DNA letter to another without double-stranded breaks. Like Rznomics, Beam operates in the precision genetic medicine space, pursuing targeted editing approaches for serious diseases with platform-based pipeline expansion.
  • Korro Bio: Biotechnology company developing RNA editing therapeutics using ADAR-mediated single-base editing. Directly comparable to Rznomics' RNA editing approach via a different enzymatic mechanism; both pursue indication-agnostic platform strategies for genetic diseases.
  • Ascidian Therapeutics: Clinical-stage company using RNA editing to treat genetic diseases by reprogramming RNA. Ascidian shares Rznomics' focus on RNA-level rather than DNA-level editing, making it a direct technology comparable in modality and therapeutic ambition.
  • ProQR Therapeutics: RNA therapeutics company developing Axiomer RNA editing technology and other RNA-targeting platforms. ProQR shares Rznomics' strategic positioning around RNA-based precision medicines and pursues similar rare disease and genetic disorder indications.
  • Wave Life Sciences: Clinical-stage company leveraging proprietary PRISM platform for RNA-targeted therapeutics including RNA editing. Wave's siRNA and RNA editing programs overlap with Rznomics' trans-splicing approach in modality and target disease areas.
  • Intellia Therapeutics: Clinical-stage gene editing company developing in vivo CRISPR/Cas9-based therapies. Comparable to Rznomics as a peer in the precision genomic medicine space, though Intellia uses DNA-level editing while Rznomics edits RNA.
  • Editas Medicine: Clinical-stage company developing CRISPR-based genome editing therapies for serious diseases. Comparable in business model (clinical-stage gene medicine developer) and therapeutic ambition, though Rznomics differentiates via RNA editing.
  • CRISPR Therapeutics: Leading clinical-stage gene editing company with approved therapy (Casgevy) and broad pipeline across hemoglobinopathies, oncology, and regenerative medicine. Comparable as a clinical-stage gene medicine company with platform technology approach.
  • Verve Therapeutics: Clinical-stage company developing in vivo base editing therapies for cardiovascular disease. Comparable as a clinical-stage precision gene medicine developer pursuing platform-based indication expansion, with similar partnership-driven commercialization model.
  • Sangamo Therapeutics: Clinical-stage genomic medicine company developing zinc finger nuclease-based gene editing and gene therapy. Comparable as a clinical-stage platform company in genomic medicine with multiple pipeline programs and partnership-based commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Rznomics social profiles

Digital presence

Rznomics compliance and trust

Trust signal

Compliance1 record

Rznomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rznomics leadership team

Management profile

Number of profiles

Profiles3 records

Rznomics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rznomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rznomics

What does Rznomics do?

Rznomics is a South Korean clinical-stage biopharmaceutical company developing RNA editing-based gene therapies, with lead candidate RZ-001 in Phase 1/2a trials for hepatocellular carcinoma and recurrent glioblastoma. The company operates a proprietary RNA trans-splicing ribozyme platform that enables precision RNA editing without permanent DNA alterations, and monetizes its pipeline primarily through licensing deals and co-development partnerships with major pharmaceutical companies such as Eli Lilly.

Is Rznomics a public or private company?

Rznomics is a public company. It is classified as public and is currently operating.

When was Rznomics founded?

Rznomics was founded in 2017. It employs 11 to 50 people.

Where is Rznomics based?

Rznomics is headquartered in Seongnam, South Korea, in the Asia region.

How does Rznomics make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are therapeutic Product Revenue.

Who are Rznomics's main competitors?

Direct peers on record are Beam Therapeutics, Korro Bio, Ascidian Therapeutics, ProQR Therapeutics, Wave Life Sciences, Intellia Therapeutics, Editas Medicine, CRISPR Therapeutics, Verve Therapeutics and Sangamo Therapeutics.

Does Rznomics have an API?

No public API is recorded for Rznomics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewRznomics Granted Orphan Medicinal Product Designation for RZ-001 for the Treatment of Glioma by the European CommissionThe European Commission granted orphan medicinal product designation to Rznomics' RZ-001 for glioma treatment, following a positive EMA opinion. The company also secured FDA orphan and fast-track designations for glioblastoma and hepatocellular carcinoma. Rznomics plans to pursue additional solid tumor indications.TradingViewRznomics Inc. Wins EU Orphan Status for RZ-001 in GliomaThe European Commission granted orphan medicinal product designation to Rznomics' RZ-001 for glioma, following a positive EMA COMP opinion. The therapy already holds FDA ODD, Fast Track for HCC and GBM, and RMAT for HCC. The designation unlocks fee reductions, protocol aid, and up to 10–12 years of exclusivity.The future of tradingRznomics’ Lee Seong-Wook and Related Parties’ Combined Stake Falls to 23.87%Lee Seong-Wook's group increased Rznomics holdings by 2,000 shares to 6,931,996 as of October 15, 2026. The group's total stake fell to 23.87% from 23.9%, while voting-share stake rose to 21.54% from 21.33%.PRESSBEERznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for Glioma ...Middle EastRznomics Inc. announced that the European Medicines Agency's Committee for Orphan Medicinal Products adopted a positive opinion on its RNA-based gene therapy RZ-001 for glioma. The opinion supports the orphan medicinal product designation for the treatment.BioSpaceRznomics Receives Positive Opinion for Orphan Medicinal Product Designation of RZ-001 for GliomaThe EMA's Committee for Orphan Medicinal Products gave a positive opinion on RZ-001 for glioma, citing Phase 1/2a data from recurrent glioblastoma patients. The therapy targets hTERT mRNA and has been administered to 13 patients. Rznomics will pursue formal designation and global development.Longevity.TechnologyRznomics makes circular RNA up to 7x more efficientRznomics researchers published a study showing their circular RNA production method improved efficiency by about sevenfold. The optimized method produced roughly twice the circularization efficiency of the previous PIE approach, enabling genes up to 7.8 kilonucleotides long. The company plans to expand the platform for applications like CAR-T therapies.BioSpaceRznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids ResearchRznomics reported a major advance in circular RNA production, published in Nucleic Acids Research on September 4, 2026. The study shows its STS technology improved circularization efficiency by up to seven-fold, achieving two-fold higher efficiency than the PIE method for Factor VIII RNA. The company plans to expand the technology across therapeutic areas, including CAR-T therapies.MorningstarRznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids ResearchRznomics announced a breakthrough in circular RNA production, published in Nucleic Acids Research on September 4, 2026. The study shows its STS technology improved circularization efficiency by up to seven-fold, and achieved two-fold higher efficiency than the PIE method for Factor VIII RNA. The company plans to expand the technology across therapeutic areas, including CAR-T therapies.PR Newswire APACRznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids ResearchRznomics reported a major advance in circular RNA production, published in Nucleic Acids Research on September 4, 2026. The study shows its STS technology improved circularization efficiency by up to seven-fold, achieving two-fold higher efficiency than the PIE method for Factor VIII RNA. The company plans to expand the technology across therapeutic areas, including CAR-T therapies.GenengnewsRznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and DevelopmentSouth Korean clinical-stage biopharmaceutical firm Rznomics has joined Lilly Gateway Labs in San Diego, an innovation hub offering wet lab facilities and access to Lilly scientists and executives. Rznomics, which develops RNA-based gene therapies, says it will accelerate candidate discovery across its database of over 200 disease targets and build global clinical infrastructure.